U.S. Markets
Gilead (GILD) executive says Anito-Cel could address an up to USD 20bln multiple myeloma opportunity when considering use in first-line treatment, via TD Conference
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
